International Journal for Computational Civil and Structural Engineering. Vol. 19. 2023. P.. 14-26
Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical 177Lu-DOTA-PSMA
The therapeutic efficacy of a Russian radiopharmaceutical 177Lu-DOTA-PSMA was studied in vivo using male BALB/c nu/nu (nude) mice with prostate carcinoma 22Rv1 xenografts by tumor growth inhibition criterion. The mean tumor volumes in mice treated with 177Lu-DOTA-PSMA were significantly lower than in animals of the control group. There were no significant differences in the values of tumor growth inhibition between the groups of animals receiving 3.7 or 7.4 MBq of 177Lu-DOTA-PSMA. © 2024, Springer Science+Business Media, LLC, part of Springer Nature.
Authors
Tishchenko V.K. , Vlasova O.P. , Lebedeva A.A. , Fedorova A.V. , Pankratov A.A. , Morozova N.B. , Kuzenkova K.A. , Stepchenkova E.D. , Shegai P.V. , Ivanov S.A. , Kaprin A.D.
Publisher
New York Consultants BureauSpringer / Автономная некоммерческая организация Издательство Российской академии медицинских наук
Issue number
2
Language
English
Pages
224-226
State
Published
Link
Volume
176
Year
2023
Organizations
- 1 A. F. Tsyb Medical Radiological Research Center — Affiliated Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Obninsk, Russian Federation
- 2 National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Obninsk, Russian Federation
- 3 P. A. Gertsen Moscow Research Oncological Institute — Branch of National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow, Russian Federation
- 4 Patrice Lumumba Peoples’ Friendship University of Russia, RUDN University), Moscow, Russian Federation
Keywords
lutetium-177; metastatic castrate-resistant prostate cancer; prostate-specific membrane antigen; radioligand therapy; radiopharmaceutical
Share